Importin 3D structures: Difference between revisions
Jump to navigation
Jump to search
No edit summary |
Michal Harel (talk | contribs) No edit summary |
||
Line 7: | Line 7: | ||
**[[1ial]] – mIPO NLS-binding domain – mouse<br /> | **[[1ial]] – mIPO NLS-binding domain – mouse<br /> | ||
**[[6d7m]] – mIPO (mutant)<br /> | |||
**[[4tnm]] – IPO armadillo repeat domain – ''Arabidopsis thaliana''<br /> | |||
**[[1bk5]] – yIPO NLS-binding domain - yeast<br /> | **[[1bk5]] – yIPO NLS-binding domain - yeast<br /> | ||
**[[ | **[[7vps]] – NgIPO ARM domain 75-516 – ''Nakaceomyces glabratus''<br /> | ||
*''IPO-α complex with NLS peptide'' | *''IPO-α complex with NLS peptide'' | ||
Line 25: | Line 27: | ||
**[[4rxh]] – NcIPO NLS-binding domain + SV40 large T antigen – ''Neurospora crassa''<br /> | **[[4rxh]] – NcIPO NLS-binding domain + SV40 large T antigen – ''Neurospora crassa''<br /> | ||
**[[5vqi]] – NcIPO NLS-binding domain + NIT2<br /> | **[[5vqi]] – NcIPO NLS-binding domain + NIT2<br /> | ||
**[[7vpt]] – NgIPO ARM domain + Upc2<br /> | |||
*''IPO-α complex with protein'' | *''IPO-α complex with protein'' | ||
Line 34: | Line 37: | ||
*IPO-α 1 | *IPO-α 1 | ||
**[[3wpt]] – hIPO NLS-binding domain - human<br /> | **[[3wpt]], [[8fzk]] – hIPO NLS-binding domain - human<br /> | ||
**[[4b8j]] – rIPO <br /> | **[[4b8j]] – rIPO <br /> | ||
**[[6bvt]] – mIPO NLS-binding domain <br /> | **[[6bvt]] – mIPO NLS-binding domain <br /> | ||
Line 47: | Line 50: | ||
**[[6bw1]] – hIPO NLS-binding domain + Hendra virus peptide<br /> | **[[6bw1]] – hIPO NLS-binding domain + Hendra virus peptide<br /> | ||
**[[5w4e]], [[5w4f]], [[5w4g]] – hIPO NLS-binding domain + polymerase peptide<br /> | **[[5w4e]], [[5w4f]], [[5w4g]] – hIPO NLS-binding domain + polymerase peptide<br /> | ||
**[[7n9h]] – hIPO NLS-binding domain + TDP-43 peptide<br /> | |||
**[[7cru]] – hIPO NLS-binding domain + hnRNPK peptide<br /> | |||
**[[8he3]] – hIPO NLS-binding domain + HIF-1 peptide<br /> | |||
**[[7n8j]] – hIPO NLS-binding domain + BIMAX peptide<br /> | **[[7n8j]] – hIPO NLS-binding domain + BIMAX peptide<br /> | ||
**[[5h43]] – hIPO NLS-binding domain + histone acetyltransferase KAT8<br /> | **[[5h43]] – hIPO NLS-binding domain + histone acetyltransferase KAT8<br /> | ||
**[[8gai]] – IPO NLS-binding domain + BIMAX peptide – guinea pig<br /> | |||
**[[4mz5]], [[4mz6]] – mIPO NLS-binding domain 70-528 + dUTPase<br /> | **[[4mz5]], [[4mz6]] – mIPO NLS-binding domain 70-528 + dUTPase<br /> | ||
**[[4oih]] – mIPO NLS-binding domain + guanine nucleotide exchange factor SRM1<br /> | **[[4oih]] – mIPO NLS-binding domain + guanine nucleotide exchange factor SRM1<br /> | ||
Line 58: | Line 65: | ||
**[[5ekg]], [[5ekf]], [[5e6q]] – mIPO NLS-binding domain + XPG2<br /> | **[[5ekg]], [[5ekf]], [[5e6q]] – mIPO NLS-binding domain + XPG2<br /> | ||
**[[5d5k]] – mIPO NLS-binding domain + PARP 2<br /> | **[[5d5k]] – mIPO NLS-binding domain + PARP 2<br /> | ||
**[[7l04]] – mIPO NLS-binding domain + adeno-associated virus<br /> | **[[7l04]], [[8fk3]] – mIPO NLS-binding domain + adeno-associated virus<br /> | ||
**[[5ctt]] – mIPO NLS-binding domain + SART3/TIP110<br /> | **[[5ctt]] – mIPO NLS-binding domain + SART3/TIP110<br /> | ||
**[[5b56]] – mIPO NLS-binding domain + HIV-1 VPR<br /> | **[[5b56]] – mIPO NLS-binding domain + HIV-1 VPR<br /> | ||
Line 67: | Line 74: | ||
**[[6iu7]], [[6iua]] – mIPO NLS-binding domain + TP53-binding protein <br /> | **[[6iu7]], [[6iua]] – mIPO NLS-binding domain + TP53-binding protein <br /> | ||
**[[5w41]] – mIPO NLS-binding domain + Zika virus peptide <br /> | **[[5w41]] – mIPO NLS-binding domain + Zika virus peptide <br /> | ||
**[[8fua]], [[8fuc]] – mIPO NLS-binding domain + Hendra virus peptide<br /> | |||
**[[8ech]] – mIPO NLS-binding domain + tick-bourne encephalitis virus<br /> | |||
**[[5v5o]], [[5v5p]] – mIPO NLS-binding domain + influenza virus peptide <br /> | **[[5v5o]], [[5v5p]] – mIPO NLS-binding domain + influenza virus peptide <br /> | ||
**[[5umz]] – mIPO NLS-binding domain + TNRC6A peptide <br /> | **[[5umz]] – mIPO NLS-binding domain + TNRC6A peptide <br /> | ||
Line 78: | Line 87: | ||
**[[7jjm]], [[7jk7]] – mIPO NLS-binding domain + LSD1 peptide <br /> | **[[7jjm]], [[7jk7]] – mIPO NLS-binding domain + LSD1 peptide <br /> | ||
**[[7jvo]] – mIPO NLS-binding domain + ACE2 peptide <br /> | **[[7jvo]] – mIPO NLS-binding domain + ACE2 peptide <br /> | ||
**[[8he0]] – mIPO NLS-binding domain + HIF-1 peptide<br /> | |||
**[[7rg4]], [[7rg5]] – mIPO NLS-binding domain + p50 peptide <br /> | **[[7rg4]], [[7rg5]] – mIPO NLS-binding domain + p50 peptide <br /> | ||
**[[6wx7]] – mIPO NLS-binding domain + SOX2 peptide <br /> | **[[6wx7]] – mIPO NLS-binding domain + SOX2 peptide <br /> | ||
Line 105: | Line 115: | ||
**[[1y2a]], [[3q5u]] – mIPO NLS-binding domain + phospholipid scramblase <br /> | **[[1y2a]], [[3q5u]] – mIPO NLS-binding domain + phospholipid scramblase <br /> | ||
**[[2c1m]] – mIPO NLS-binding domain + Nup50<br /> | **[[2c1m]] – mIPO NLS-binding domain + Nup50<br /> | ||
**[[7leq]] – mIPO NLS-binding domain + p50<br /> | |||
**[[7leu]] – mIPO NLS-binding domain + p65<br /> | |||
**[[3btr]] – mIPO NLS-binding domain + androgen receptor<br /> | **[[3btr]] – mIPO NLS-binding domain + androgen receptor<br /> | ||
**[[3knd]] – mIPO NLS-binding domain + targeting protein for KXLP2<br /> | **[[3knd]] – mIPO NLS-binding domain + targeting protein for KXLP2<br /> | ||
Line 113: | Line 125: | ||
**[[3tpm]] – mIPO NLS-binding domain + MAL<br /> | **[[3tpm]] – mIPO NLS-binding domain + MAL<br /> | ||
**[[3ve6]] – mIPO NLS-binding domain + Venezuelan equine encephalitis virus<br /> | **[[3ve6]] – mIPO NLS-binding domain + Venezuelan equine encephalitis virus<br /> | ||
**[[8f2q]] – mIPO NLS-binding domain + parvovirus<br /> | |||
**[[3uvu]] – mIPO NLS-binding domain + flap endonuclease<br /> | **[[3uvu]] – mIPO NLS-binding domain + flap endonuclease<br /> | ||
**[[3ukw]], [[3ukx]] – mIPO NLS-binding domain + BIMAX<br /> | **[[3ukw]], [[3ukx]] – mIPO NLS-binding domain + BIMAX<br /> | ||
Line 135: | Line 148: | ||
**[[6bvv]] – hIPO NLS-binding domain + Nipa virus peptide<br /> | **[[6bvv]] – hIPO NLS-binding domain + Nipa virus peptide<br /> | ||
**[[5xzx]] – hIPO NLS-binding domain + RAN-binding protein peptide<br /> | **[[5xzx]] – hIPO NLS-binding domain + RAN-binding protein peptide<br /> | ||
**[[8hkw]] – hIPO NLS-binding domain + 53BP1 peptide<br /> | |||
**[[5tbk]] – hIPO NLS-binding domain + regulator of chromosome condensation <br /> | **[[5tbk]] – hIPO NLS-binding domain + regulator of chromosome condensation <br /> | ||
**[[7rfy]] – hIPO + ORF4b<br /> | **[[7rfy]] – hIPO + ORF4b<br /> | ||
**[[6wx8]] – hIPO + SOX2<br /> | **[[6wx8]] – hIPO + SOX2<br /> | ||
**[[7lfc]] – hIPO + p50 NLS<br /> | |||
**[[7lf4]] – hIPO + p50 NLS + p65 NLS<br /> | |||
**[[8fub]] – hIPO NLS-binding domain + Hendra virus peptide<br /> | |||
**[[8fzm]] – mIPO NLS-binding domain + BIMAX<br /> | |||
**[[7let]] – mIPO + p50 NLS + p65 NLS<br /> | |||
*IPO-α 5 | *IPO-α 5 | ||
Line 149: | Line 168: | ||
*IPO-α 7 | *IPO-α 7 | ||
**[[7rht]] – hIPO <br /> | |||
**[[4uad]] – hIPO NLS-binding domain + influenza RNA polymerase<br /> | **[[4uad]] – hIPO NLS-binding domain + influenza RNA polymerase<br /> | ||
*IPO-β | *IPO-β | ||
**[[4xrk]] – IPO – ''Chaetomium thermophilum'' <br /> | **[[4xri]], [[4xrk]] – IPO – ''Chaetomium thermophilum'' <br /> | ||
*IPO-β 1 (karyopherin β 1) | *IPO-β 1 (karyopherin β 1) | ||
Line 207: | Line 227: | ||
**[[7jjl]] – hIPO + LSD1 peptide <br /> | **[[7jjl]] – hIPO + LSD1 peptide <br /> | ||
*IPO-4 | |||
**[[8dyo]] – hIPO + RanGTP – Cryo EM<br /> | |||
**[[7unk]] – hIPO + H3 + H4 + ASF1 – Cryo EM<br /> | |||
*IPO-4B | *IPO-4B | ||
Line 230: | Line 255: | ||
**[[4c0o]] – hIPO + serine/arginine-rich splicing factor<br /> | **[[4c0o]] – hIPO + serine/arginine-rich splicing factor<br /> | ||
**[[4c0q]], [[4ol0]] – hIPO + GTPase Ran<br /> | **[[4c0q]], [[4ol0]] – hIPO + GTPase Ran<br /> | ||
**[[6gx9]] – hIPO + CPSF 68<br /> | |||
*IPO-13 (karyopherin 13) | *IPO-13 (karyopherin 13) |
Revision as of 10:10, 29 May 2023
3D structures of importin3D structures of importin
Updated on 29-May-2023